GumGum Accelerates Global Expansion by Acquiring JustPremium
10.8.2021 13:18:00 EEST | Business Wire | Press release
GumGum, the leader in contextual intelligence technology, announced the acquisition of JustPremium, one of the largest rich media and video ad marketplaces in Europe. Their combined offering makes them one of the only global providers with a unified solution delivering attention-grabbing ad creatives in contextually relevant digital environments across global campaigns.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210810005518/en/
Contextual targeting is set to be a $412 billion business by 2025 and both GumGum and JustPremium have seen significant growth as the industry has rapidly accelerated its shift to contextual technology and attention first digital advertising solutions. GumGum’s 2021 revenue alone is on track to grow over 40% compared to last year. With the addition of JustPremium, GumGum expedites that growth and furthers its position as a global strategic partner. Together they will lead the industry in offering a comprehensive solution that leverages both contextual and creative to deliver campaigns that are dynamically placed and drive consumer attention across digital environments for video, display, and CTV. Their first combined offering will include a new high impact in-content (outstream) video ad unit, which will be the first to be powered by Verity, GumGum’s accredited contextual data solution.
“Brands are looking for a strategic partner with value tested and accredited technology that drives campaign results, with no reliance on cookies, on a global scale. We believe this acquisition makes us that partner,” said Phil Schraeder, Chief Executive Officer, GumGum. “It’s all about creative, context, and global scale. With those three elements, powered by sophisticated technology, we deliver what consumers want across all digital environments and, as a result, drive strong campaign ROAS for our brand partners.”
This acquisition is an integral part of GumGum’s global growth strategy. JustPremium helps some of the world’s most powerful brands connect with more than 900 million people in premium environments. By joining forces with JustPremium, GumGum doubles its brand and publishers presence in the U.K. and will expand into eight new markets including Germany, France, Spain, Netherlands, Belgium, Sweden, Denmark, and Mexico.
“Over the past 9 years, we have built a successful business based on making it simple to create, buy and deliver memorable ads with a portfolio of high-impact video and display formats running on a global network of premium publishers. With GumGum, we will now be able to maximize that vision by expanding our global reach and pairing our creative offering with an accredited industry-leading contextual engine that will meet the needs of what advertisers and publishers have been asking for,” said Eric Visser, Chief Executive Officer, JustPremium.
JustPremium is a European-based company, headquartered in Amsterdam, with approximately 150 employees globally. JustPremium’s CEO, Eric Visser will stay on as the President of EMEA for GumGum and report to Phil Schraeder, GumGum’s CEO. JustPremium’s organization and name will be integrated under the GumGum brand.
For more information please reach out to pr@gumgum.com.
Regional quotes:
For Germany: "We've been present in Germany for over seven years and have earned the top position for programmatic Rich Media here. We are currently partnering with over 400 premium websites and in 2020 we ran local campaigns with almost 600 national and international buyers. The acquisition of JustPremium by GumGum creates the perfect platform to drive further growth in the region. The conversation on data and creativity working hand in hand has grown ever more in recent years. By combining GumGum’s industry-leading accredited contextual technology with our leading rich media marketplace, we are primed to offer advertisers a cookie-free, attention-grabbing solution that will drive significant benefits for their business in Germany and abroad,” said Joerg Schneider, Global Head of Sales & Supply at JustPremium
For Switzerland and Austria: “The acquisition of JustPremium by GumGum creates the perfect platform to drive further growth in the region. The conversation on data and creativity working hand in hand has grown ever more in recent years. By combining GumGum’s industry-leading accredited contextual technology with our leading rich media marketplace, we are primed to offer advertisers a cookie-free, attention-grabbing solution that will drive significant benefits for their business in the region and beyond,” said Joerg Schneider, Global Head of Sales & Supply at JustPremium
For France: “We entered the French market a few months before COVID-19 took over the world. Nevertheless we managed to partner with over 200 premium websites and activate campaigns with over 250 national and international buyers. The acquisition of JustPremium by GumGum creates the perfect platform to drive even faster growth in France. The conversation on data and creativity working hand in hand has grown ever more in recent years. By combining GumGum’s industry-leading accredited contextual data technology with our leading rich media marketplace, we are primed to offer advertisers a cookie-free, attention-grabbing solution that will drive significant benefits for their business in France and abroad,” Eric Visser, Chief Executive Officer, JustPremium.
For Spain: “We have been active in the Spanish market for over five years with Ikreate as our in-market representative. Together we are currently partnering with over 150 premium websites. In 2020, we managed to activate local campaigns with almost 400 national and international buyers. The acquisition of JustPremium by GumGum creates the perfect platform to drive further growth in Spain. The conversation on data and creativity working hand in hand has grown ever more in recent years. By combining GumGum’s industry-leading accredited contextual technology with our leading rich media marketplace, we are primed to offer advertisers a cookie-free, attention-grabbing solution that will drive significant benefits for their business in Spain and abroad,” Eric Visser, Chief Executive Officer, JustPremium.
For Belgium: “We have been active in our neighbouring country for over six years now and have built long lasting partnerships with leading agencies and premium advertisers. In 2020, over 350 national and international buyers ran their local campaigns with us. The acquisition of JustPremium by GumGum creates the perfect platform to drive further growth in Belgium. The conversation on data and creativity working hand in hand has grown ever more in recent years. By combining GumGum’s industry-leading accredited contextual data technology with our leading rich media marketplace, we are primed to offer advertisers a cookie-free, attention-grabbing solution that will drive significant benefits for their business in Belgium and abroad,” said Eric Visser, Chief Executive Officer.
For Netherlands: "Nine years ago we started JustPremium with the goal to make it easy for Dutch advertisers to buy Rich Media at scale. Fuelled by our ambition to build a global company, we opened offices in London, Dusseldorf, Brussels, New York, and nine other cities without any external investor. Today we have over 140 employees, from 30 nationalities, working with leading brands and premium publishers in more than 24 countries. The acquisition of JustPremium by GumGum creates the perfect platform to drive our growth in these markets, including our home in the Netherlands. The conversation on data and creativity working hand in hand has grown ever more in recent years. By combining GumGum’s industry-leading accredited contextual data technology with our leading rich media marketplace, we are primed to offer advertisers a cookie-free, attention-grabbing solution that will drive significant benefits for their business both national and international,” said Eric Visser, Chief Executive Officer, JustPremium.
For Sweden and Denmark: “We have been active in the Nordics for over six years now and currently partner with over 200 premium websites. In 2020, we managed to activate local campaigns with almost 250 national and international buyers. The acquisition of JustPremium by GumGum creates the perfect platform to drive further growth in the Nordics. The conversation on data and creativity working hand in hand has grown ever more in recent years. By combining GumGum’s industry-leading accredited contextual data technology with our leading rich media marketplace, we are primed to offer advertisers a cookie-free, attention-grabbing solution that will drive significant benefits for their business in the Nordics and abroad,” said Eric Visser, Chief Executive Officer, JustPremium.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005518/en/
Contact information
Lydia Oakes
lydia.oakes@bluestripegroup.co.uk
07710244573
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
